MMP-9 and MMP-2 Gelatinases and TIMP-1 and TIMP-2 Inhibitors in Breast Cancer: Correlations with Prognostic Factors

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2006 Jun 27

PMID 16796815

Citations 53

Authors

D C Jinga

A Blidaru

Ileana Condrea

Carmen Ardeleanu

Cristina Dragomir

G Szegli

Maria Stefanescu

Cristiana Matache

Affiliations

Soon will be listed here.

Abstract

The goal of our study was to analyse the prognostic values for some matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in breast cancer. We evaluated the activity and the expression levels of MMP-9, MMP-2, TIMP-1 and TIMP-2 in malignant versus benign fresh breast tumor extracts. For this purpose, gelatinzymography, immunoblotting and ELISA were used to analyse the activity and expression of MMPs and TIMPs. We found that MMP-9 expression level and activity are increased in malignant tumors. In addition, MMP-9/TIMP-1 and MMP-2/TIMP-2 ratio values obtained by us were significantly different in malignant tumors compared to benign tumors. We suggest that the abnormal MMP-9/TIMP-1 balance plays a role in the configuration of breast invasive carcinoma of no special type and also in tumor growth, while altered MMP-2/TIMP-2 ratio value could be associated with lymph node invasion and used as a prognostic marker in correlation with Nottingham Prognostic Index. Finally, we showed that in malignant tumors high expression of estrogen receptors is associated with enhanced activity of MMP-2 and increased bcl- 2 levels, while high expression of progesterone receptors is correlated with low TIMP-1 protein levels.

Citing Articles

Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.

Weijie S Discov Oncol. 2024; 15(1):783.

PMID: 39692932 PMC: 11655786. DOI: 10.1007/s12672-024-01693-8.

Identification and validation of matrix metalloproteinase hub genes as potential biomarkers for Skin Cutaneous Melanoma.

Zhang Z, Zhao M, Zhou Z, Ren X, He Y, Shen T Front Oncol. 2024; 14:1471267.

PMID: 39493455 PMC: 11527786. DOI: 10.3389/fonc.2024.1471267.

Comparing CD10 Expression With the Clinicopathological Features and Hormone Status of Invasive Breast Cancer.

Kumaravel A, Esakki M Cureus. 2024; 16(9):e69836.

PMID: 39435217 PMC: 11492156. DOI: 10.7759/cureus.69836.

Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy.

Olah O, Majlat E, Koszo R, Vereb Z, Voros A Pathol Oncol Res. 2023; 28:1610598.

PMID: 36685105 PMC: 9849231. DOI: 10.3389/pore.2022.1610598.

Inhibition of cell invasion and migration by targeting matrix metalloproteinase-9 expression via sirtuin 6 silencing in human breast cancer cells.

Hong O, Jang H, Lee Y, Jung S, Youn H, Kim J Sci Rep. 2022; 12(1):12125.

PMID: 35840633 PMC: 9287314. DOI: 10.1038/s41598-022-16405-x.

References

Bussolati G, Gugliotta P . Nonspecific staining of mast cells by avidin-biotin-peroxidase complexes (ABC). J Histochem Cytochem. 1983; 31(12):1419-21. DOI: 10.1177/31.12.6195216. View

Nakopoulou L, Michalopoulou A, Giannopoulou I, Tzonou A, Keramopoulos A, Lazaris A . bcl-2 protein expression is associated with a prognostically favourable phenotype in breast cancer irrespective of p53 immunostaining. Histopathology. 1999; 34(4):310-9. DOI: 10.1046/j.1365-2559.1999.00627.x. View

Xu X, Wang Y, Chen Z, Sternlicht M, Hidalgo M, Steffensen B . Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. Cancer Res. 2005; 65(1):130-6. View

Stetler-Stevenson W, Bersch N, Golde D . Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett. 1992; 296(2):231-4. DOI: 10.1016/0014-5793(92)80386-u. View

Kuvaja P, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T . The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma. Oncology. 2005; 68(2-3):196-203. DOI: 10.1159/000086774. View

George S . Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs. 2000; 9(5):993-1007. DOI: 10.1517/13543784.9.5.993. View

Giannelli G, Erriquez R, Fransvea E, Daniele A, Trerotoli P, Schittulli F . Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer. 2004; 109(5):782-5. DOI: 10.1002/ijc.20009. View

Baker A, Zaltsman A, George S, Newby A . Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest. 1998; 101(6):1478-87. PMC: 508704. DOI: 10.1172/JCI1584. View

Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K . Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992; 298(1):29-32. DOI: 10.1016/0014-5793(92)80015-9. View

10.

Liu X, Taube M, Jung K, Dong Z, Lee Y, Roshy S . Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res. 2005; 65(3):898-906. View

11.

Garbett E, Reed M, Stephenson T, Brown N . Proteolysis in human breast cancer. Mol Pathol. 2000; 53(2):99-106. PMC: 1186913. DOI: 10.1136/mp.53.2.99. View

12.

McCawley L, Matrisian L . Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol. 2001; 13(5):534-40. DOI: 10.1016/s0955-0674(00)00248-9. View

13.

Furberg A, Ambrosone C . Molecular epidemiology, biomarkers and cancer prevention. Trends Mol Med. 2001; 7(11):517-21. DOI: 10.1016/s1471-4914(01)02162-1. View

14.

Fitzgibbons P, Page D, Weaver D, Thor A, Allred D, Clark G . Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124(7):966-78. DOI: 10.5858/2000-124-0966-PFIBC. View

15.

McCawley L, Matrisian L . Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000; 6(4):149-56. DOI: 10.1016/s1357-4310(00)01686-5. View

16.

Baker E, Stephenson T, Reed M, Brown N . Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol. 2002; 55(5):300-4. PMC: 1187260. DOI: 10.1136/mp.55.5.300. View

17.

Struse K, Audretsch W, Rezai M, Pott G, Bojar H . The Estrogen Receptor Paradox in Breast Cancer: Association of High Receptor Concentrations with Reduced Overall Survival. Breast J. 2001; 6(2):115-125. DOI: 10.1046/j.1524-4741.2000.99060.x. View

18.

Rha S, Yang W, Kim J, Roh J, Min J, Lee K . Different expression patterns of MMP-2 and MMP-9 in breast cancer. Oncol Rep. 1998; 5(4):875-9. DOI: 10.3892/or.5.4.875. View

19.

McCarthy K, Maguire T, McGreal G, McDermott E, OHiggins N, Duffy M . High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer. 1999; 84(1):44-8. DOI: 10.1002/(sici)1097-0215(19990219)84:1<44::aid-ijc9>3.0.co;2-p. View

20.

Jones J, Glynn P, Walker R . Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999; 189(2):161-8. DOI: 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2. View